Repligen Signals Confident Growth Path In 2026 Outlook

Repligen ((RGEN)) has held its Q4 earnings call. Read on for the main highlights of the call.

Repligen’s latest earnings call struck a notably upbeat tone, with management highlighting faster‑than‑expected revenue growth, expanding margins, and strong cash generation. Executives acknowledged pockets of macro and sector pressure, but repeatedly emphasized broad‑based strength across franchises and a disciplined, realistic outlook for 2026.

Quarter and Full‑Year Revenue Growth

Repligen delivered Q4 revenue of $198M, up 18% on a reported basis and 14% organically versus last year, signaling a clear acceleration into year‑end. For full‑year 2025, revenue reached $738M, rising 16% both reported and on an organic non‑COVID basis, showing the core business is driving growth.

Strong Franchise Performance

Growth was broad, with Proteins and Analytics each posting more than 30% revenue gains in Q4 and full‑year growth of 31% and 37%, respectively, supported by the 908 Devices acquisition. Chromatography advanced over 25% in Q4 and 25% for the year, while Filtration grew at high single digits in the quarter and 8% for the year, or 11% excluding COVID headwinds, and consumables rose more than 20%.

Margin Expansion and Profitability

Profitability moved higher alongside growth, with Q4 adjusted gross margin at 52.4%, up 170 basis points year over year, and full‑year gross margin at 52.6%, roughly 220 basis points higher. Adjusted operating margin for 2025 reached 13.8%, up 90 basis points reported and about 240 basis points excluding M&A and FX, driving an adjusted EBITDA margin of 19%.

Cash Generation and Balance Sheet Strength

The company exited the year with $768M in cash and marketable securities, up $90M sequentially, underscoring financial flexibility for investment and M&A. Full‑year operating cash flow totaled $117M, including $26M generated in Q4 against $8M of capital expenditures, signaling disciplined spending and solid free‑cash‑flow dynamics.

Product Innovation and Go‑to‑Market Execution

Management leaned heavily on innovation and commercial execution, citing multiple 2025 launches such as SoloVPE PLUS, ProConnex MixOne, and three new catalog resins. Early traction in the SoloVPE PLUS upgrade cycle remains modest, with fewer than 100 upgrades out of an installed base of 1,500–2,000 units, but the sales force is now cross‑selling 2.5 times more product lines into key accounts versus 2019.

M&A and Strategic Partnerships Progress

Repligen continued to deepen its toolkit through acquisitions and partnerships, including the purchase of 908 Devices’ bioprocessing portfolio and ongoing integration of Tantti. A strategic partnership and minority stake in Novasign aims to embed machine learning into filtration systems, and overall M&A activity contributed about one point to reported revenue growth in 2025.

Commercial Funnel and Strategic Priorities

Management described the company’s high‑probability commercial funnel as the strongest in its history, with more opportunities now classified at greater than 50% win likelihood. Strategic priorities include heavier cross‑selling, expansion in Asia Pacific, growing services from roughly 6% of 2025 sales toward 10% over time, and Fit‑for‑Growth investments in AI, IT, and leadership to support scale.

Muted Capital Equipment and Downstream Demand

Not all end‑markets are firing, as capital equipment revenue was essentially flat year over year despite a 10% sequential uptick in Q4. Management noted continued muted demand and challenging comparisons in downstream systems, and they currently expect downstream and broader CapEx‑linked businesses to remain roughly flat through 2026 without a macro tailwind.

Gene Therapy Customer Headwind

A single gene therapy platform is creating a measurable drag, and management explicitly baked this into the outlook. They estimate the issue trims about two points from overall 2026 revenue growth guidance and roughly three points from Filtration growth, contributing to a more cautious revenue pacing in the first half of the year.

Tariffs, Policy Uncertainty and Regulatory Overhang

Executives flagged a more unsettled policy backdrop, pointing to tariff regimes and related legal developments as a source of volatility. The company expects several million dollars in tariff surcharges in 2026, representing roughly a 50‑basis‑point headwind to margins, and cautioned that large pharma customers may delay major CapEx decisions as they digest policy shifts, adding risk to near‑term growth cadence.

M&A and FX Dilution to Near‑Term Margins

While acquisitions are boosting growth and expanding the portfolio, they are also temporarily diluting reported profitability. Management said adjusted operating margin would have expanded about 240 basis points year over year excluding M&A and FX, implying that deal‑related OpEx, integration costs, and currency collectively masked much stronger underlying leverage and accounted for roughly $19M of additional expense.

OpEx Step‑Up and Investment Spend

Operating expenses increased by about $49M year over year as Repligen leaned into its Fit‑for‑Growth strategy, including spend on legal, finance, IT, and AI capabilities, alongside normal merit and compensation inflation that represented roughly five percentage points of the increase. Management guided to another OpEx step‑up in Q1 2026 tied to annual compensation resets and growth investments, with spending expected to be flat to modestly higher thereafter.

Market and Regional Headwinds

The company acknowledged that certain modalities and geographies are still lagging, with mRNA‑related demand remaining a headwind for new modalities. China, though improving for two consecutive quarters, still accounts for only about 2%–3% of revenue as Repligen continues rebuilding its commercial footprint, suggesting any acceleration from that region will come off a relatively small base.

Interest and Other Income Pressure

Below the operating line, Repligen is seeing some offset to its operational gains from lower interest income as rates drift down. Management expects adjusted other income of around $18M in 2026 after 2025 already reflected about $2M less interest income than the prior year, slightly tempering the benefit from expanding operating margins.

2026 Guidance and Outlook

For 2026, Repligen guided revenue to $810M–$840M, representing 10%–14% reported growth and 9%–13% organically, with about a one‑point FX tailwind and a multi‑point gene therapy drag. The company projects adjusted gross margin between 53.6% and 54.1%, roughly 125 basis points higher at the midpoint despite a tariff headwind, adjusted operating income of $122M–$130M, EPS of $1.93–$2.01, and CapEx at 3%–4% of sales, with about 48% of revenue expected in the first half.

Repligen’s call painted a picture of a life‑science supplier balancing strong underlying demand and improving profitability with a pragmatic view of macro and sector‑specific risks. For investors, the key takeaways are double‑digit growth, expanding margins, a robust balance sheet, and a disciplined approach to investment and M&A that together support a constructive, if measured, outlook into 2026.